Please use this identifier to cite or link to this item:
|Title:||A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant|
|Authors:||Davis, Ian D;Quirk, Juliet;Morris, Leone;Seddon, Lauren;Tai, Tsin Yee;Whitty, Genevieve;Cavicchiolo, Tina;Ebert, Lisa;Jackson, Heather;Browning, Judy;MacGregor, Duncan;Wittke, Frederick;Winkels, Gregor;Alex, Regina;Miloradovic, Lena;Maraskovsky, Eugene;Chen, Weisan;Cebon, Jonathan S|
|Citation:||Immunotherapy 2017; 9(3): 249-259|
|Abstract:||Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. PATIENTS & METHODS: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. RESULTS: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. CONCLUSION: This method was feasible and safe but was minimally immunogenic.|
|Type of Clinical Study or Trial:||Clinical Trial|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.